GLPwatch
Treating diabetes mellitus in Prader-Willi syndrome with Exenatide.
Diabetes Res Clin Pract · 2011
Last updated 2026-05-28A 19-year-old woman with Prader-Willi syndrome and diabetes was treated with Exenatide, a GLP-1 drug. The treatment helped reduce her weight and appetite, which may be useful for managing obesity and diabetes in people with this condition.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2011 |
|---|---|
| Citations | 25 |
| Relative citation ratio | 0.85 |
| NIH percentile | 45 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
We report the use of Exenatide, a GLP-1 agonist, in the management of diabetes mellitus in a 19 year-old female with Prader-Willi syndrome. The beneficial effects of Exenatide in weight reduction and appetite suppression provide a promising strategy for the treatment of obesity and diabetes mellitus in Prader-Willi syndrome.
Verbatim abstract via PubMed 21227526 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.